Some studies have confirmed that patients with high USP35 expression in ovarian cancer, liver cancer, clear cell renal cell carcinoma, and cutaneous melanoma have a poor prognosis [16, 21–23]. This evidence concerns the gene USP35 and ovarian carcinoma.